ATE454143T1 - Enos-transkriptionsverstärker zur verwendung in der zelltherapie von ischämischen herzerkrankungen - Google Patents

Enos-transkriptionsverstärker zur verwendung in der zelltherapie von ischämischen herzerkrankungen

Info

Publication number
ATE454143T1
ATE454143T1 AT04818113T AT04818113T ATE454143T1 AT E454143 T1 ATE454143 T1 AT E454143T1 AT 04818113 T AT04818113 T AT 04818113T AT 04818113 T AT04818113 T AT 04818113T AT E454143 T1 ATE454143 T1 AT E454143T1
Authority
AT
Austria
Prior art keywords
heart disease
cell therapy
ischemic heart
enos transcription
amplifier
Prior art date
Application number
AT04818113T
Other languages
English (en)
Inventor
Andreas Zeiher
Stefanie Dimmeler
Christopher Heeschen
Hartmut Ruetten
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of ATE454143T1 publication Critical patent/ATE454143T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT04818113T 2003-11-06 2004-10-22 Enos-transkriptionsverstärker zur verwendung in der zelltherapie von ischämischen herzerkrankungen ATE454143T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03025512A EP1529525A1 (de) 2003-11-06 2003-11-06 ENOS Transkriptionsenhancer zur Zellentherapie-Behandlung von Ischämischer Herzerkrankungen
PCT/EP2004/011944 WO2005044249A1 (en) 2003-11-06 2004-10-22 Enos transcription enhancers for use in the cell therapy of ischemic heart diseases

Publications (1)

Publication Number Publication Date
ATE454143T1 true ATE454143T1 (de) 2010-01-15

Family

ID=34429288

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04818113T ATE454143T1 (de) 2003-11-06 2004-10-22 Enos-transkriptionsverstärker zur verwendung in der zelltherapie von ischämischen herzerkrankungen

Country Status (21)

Country Link
EP (3) EP1529525A1 (de)
JP (1) JP4705581B2 (de)
KR (1) KR101133943B1 (de)
CN (1) CN100563643C (de)
AR (1) AR046572A1 (de)
AT (1) ATE454143T1 (de)
AU (1) AU2004286776B2 (de)
BR (1) BRPI0416313A (de)
CA (1) CA2544632C (de)
CY (1) CY1112015T1 (de)
DE (1) DE602004025024D1 (de)
DK (1) DK1682111T3 (de)
ES (1) ES2339252T3 (de)
IL (1) IL174807A (de)
PE (1) PE20050486A1 (de)
PL (1) PL1682111T3 (de)
PT (1) PT1682111E (de)
SI (1) SI1682111T1 (de)
TW (1) TW200528119A (de)
UY (1) UY28605A1 (de)
WO (1) WO2005044249A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1529525A1 (de) 2003-11-06 2005-05-11 Aventis Pharma Deutschland GmbH ENOS Transkriptionsenhancer zur Zellentherapie-Behandlung von Ischämischer Herzerkrankungen
JP4487051B2 (ja) 2005-08-29 2010-06-23 独立行政法人科学技術振興機構 ダチョウを用いた抗体、及びその作製方法
WO2014042292A1 (ko) * 2012-09-12 2014-03-20 연세대학교 산학협력단 단백질 인산화효소 c 활성화제를 포함하는 줄기세포 부착 촉진용 조성물 및 줄기세포의 부착 촉진 방법
GB201601301D0 (en) * 2016-01-25 2016-03-09 Takeda Pharmaceutical Novel compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2368677C (en) * 1999-03-30 2012-07-10 Ran Kornowski Intramyocardial injection of autologous bone marrow
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
AR035431A1 (es) * 2001-02-13 2004-05-26 Aventis Pharma Gmbh 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas, un metodo para su sintesis, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos
TWI241190B (en) * 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
PE20020856A1 (es) * 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-tetrahidronaftil aminas aciladas
EP1529525A1 (de) 2003-11-06 2005-05-11 Aventis Pharma Deutschland GmbH ENOS Transkriptionsenhancer zur Zellentherapie-Behandlung von Ischämischer Herzerkrankungen

Also Published As

Publication number Publication date
EP1529525A1 (de) 2005-05-11
TW200528119A (en) 2005-09-01
EP2198861B1 (de) 2014-06-25
CA2544632C (en) 2012-09-04
KR20060108658A (ko) 2006-10-18
CA2544632A1 (en) 2005-05-19
CY1112015T1 (el) 2015-11-04
CN100563643C (zh) 2009-12-02
ES2339252T3 (es) 2010-05-18
PE20050486A1 (es) 2005-10-06
AR046572A1 (es) 2005-12-14
PL1682111T3 (pl) 2010-06-30
BRPI0416313A (pt) 2006-12-26
WO2005044249A1 (en) 2005-05-19
SI1682111T1 (sl) 2010-04-30
CN1878544A (zh) 2006-12-13
JP2007509873A (ja) 2007-04-19
IL174807A0 (en) 2008-04-13
IL174807A (en) 2011-05-31
PT1682111E (pt) 2010-02-10
EP1682111A1 (de) 2006-07-26
KR101133943B1 (ko) 2012-04-13
EP2198861A3 (de) 2010-12-15
AU2004286776A1 (en) 2005-05-19
UY28605A1 (es) 2005-05-31
AU2004286776B2 (en) 2010-05-27
DK1682111T3 (da) 2010-04-26
JP4705581B2 (ja) 2011-06-22
HK1095527A1 (zh) 2007-05-11
EP2198861A2 (de) 2010-06-23
DE602004025024D1 (de) 2010-02-25
EP1682111B1 (de) 2010-01-06

Similar Documents

Publication Publication Date Title
DE50306850D1 (de) Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
ATE448206T1 (de) Benzochinazolinderivate und ihre verwendung bei der behandlung von knochenerkrankungen
ATE426411T1 (de) Neue verwendung von erythropoietin in herzerkrankungen
DE50310980D1 (de) VERWENDUNG VON I kappa B-KINASE INHIBITOREN IN DER SCHMERZTHERAPIE
DK2348103T3 (da) Fremgangsmåder til anvendelse af regenerative celler til behandling af perifer karsygdom og beslægtede sygdomme
NO20081842L (no) Fremgangsmåter og sammensetninger for anvendelse ved behandling av pasienter med autoantistoff-positive sykdommer
DK1575951T3 (da) Heterocykliske forbindelser, fremgangsmåder til fremstilling deraf og deres anvendelse i terapi
ATE389649T1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
DK1799235T3 (da) Sammensætninger af fosterhudcelleprotein til behandling af hudtilstande, -lidelser eller -sygdomme og fremgangsmåder til fremstilling og anvendelse deraf
DE602005022859D1 (de) Heteroarylbenzamidderivate zur verwendung als glk-aktivatoren bei der behandlung von diabetes
EP1722681A4 (de) Verfahren und vorrichtungen für die nichtinvasive messung von quantitativen informationen von substanzen in lebenden organismen
ATE372998T1 (de) 1-aminophthalazinderivate, deren herstellung und deren therapeutische verwendung
DE602005008419D1 (de) Verwendung von meloxicam-formulierungen in der veterinärmedizin
DE60325967D1 (de) Stimulierung von hämatopoiese bei ex vivo aktivierten immunzellen
DE602004027637D1 (de) Verwendung von cupredoxin-proteine für krebstherapie
EP1708757A4 (de) Verwendung von aus humanem nabelschnurblut gewonnenen pluripotenten zellen zur behandlung von krankheit
IS7916A (is) Arýl alkýl karbamat afleiður framleiðslu og notkun þeirra í meðferð
DK1708994T3 (da) Aryloxyalkylcarbamatderivater, fremstilling og anvendelse herfra inden for terapi
ATE454143T1 (de) Enos-transkriptionsverstärker zur verwendung in der zelltherapie von ischämischen herzerkrankungen
DE60327084D1 (de) Verwendung von n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-ä1,3,4-oxadiazol-2-ylüphenyl)pyridin-3-sulphonamid in der tumortherapie
ATE483460T1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
EP1590440A4 (de) Zellabtötende moleküle und vefahren zu deren verwendung
DE602006008566D1 (de) EKG-Aufnahmegerät und Verwendungsverfahren
DE602005014715D1 (de) Methode zur Messung von Haut Anisotropie

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1682111

Country of ref document: EP